Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

Investigational Site Number 1580004, Taipei

Investigational Site Number 1580002, Taipei

Investigational Site Number 1580003, Taipei

Investigational Site Number 4100012, Gyeonggi-do

Investigational Site Number 4100002, Wŏnju

Investigational Site Number 1580001, Taichung

Investigational Site Number 4100010, Gwangju

Investigational Site Number 1560039, Beijing

Investigational Site Number 1560001, Beijing

Investigational Site Number 1560017, Beijing

Investigational Site Number 1560003, Beijing

Investigational Site Number 1560048, Shenyang

Investigational Site Number 1560005, Shenyang

Investigational Site Number 1560033, Changchun

Investigational Site Number 1560013, Siping

Investigational Site Number 1560021, Shanghai

Investigational Site Number 1560018, Shanghai

Investigational Site Number 1560002, Nanjing

Investigational Site Number 1560012, Nanjing

Investigational Site Number 1560047, Nanjing

Investigational Site Number 1560030, Zhenjiang

Investigational Site Number 1560016, Changzhou

Investigational Site Number 1560049, Changzhou

Investigational Site Number 1560010, Xuzhou

Investigational Site Number 1560046, Hefei

Investigational Site Number 1560019, Jinan

Investigational Site Number 1560023, Tianjin

Investigational Site Number 1560044, Tianjin

Investigational Site Number 1560024, Hangzhou

Investigational Site Number 1560038, Nanchang

Investigational Site Number 1560045, Nanchang

Investigational Site Number 1560006, Fuzhou

Investigational Site Number 1560034, Xiamen

Investigational Site Number 1560041, Zhuzhou

Investigational Site Number 1560026, Yueyang

Investigational Site Number 1560011, Zhengzhou

Investigational Site Number 1560004, Guangzhou

Investigational Site Number 1560036, Guangzhou

Investigational Site Number 1560043, Guangzhou

Investigational Site Number 1560014, Guangzhou

Investigational Site Number 1560020, Shenzhen

Investigational Site Number 1560042, Guiyang

Investigational Site Number 1560009, Xi'an

Investigational Site Number 1560027, Lanzhou

Investigational Site Number 1560025, Hohhot

Investigational Site Number 1560031, Tangshan

Investigational Site Number 4100003, Anyang

Investigational Site Number 4100005, Busan

Investigational Site Number 4100008, Seoul

Investigational Site Number 4100001, Seoul

Investigational Site Number 4100009, Seoul

Investigational Site Number 4100004, Seoul

Investigational Site Number 4100006, Seoul

Investigational Site Number 4100007, Seoul